TY - JOUR
T1 - Improving survival rates of patients with idiopathic dilated cardiomyopathy in tuscany over 3 decades
T2 - Impact of evidence-based management
AU - Castelli, Gabriele
AU - Fornaro, Alessandra
AU - Ciaccheri, Mauro
AU - Dolara, Alberto
AU - Troiani, Vito
AU - Tomberli, Benedetta
AU - Olivotto, Iacopo
AU - Gensini, Gian Franco
PY - 2013/9
Y1 - 2013/9
N2 - Background-Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure. However, limited evidence is available specifically on idiopathic dilated cardiomyopathy. We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years. Methods and Results-From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years. Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001- 2011 (n=238). Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P
AB - Background-Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure. However, limited evidence is available specifically on idiopathic dilated cardiomyopathy. We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years. Methods and Results-From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years. Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001- 2011 (n=238). Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P
KW - Cardiac resynchronization therapy
KW - Cardiomyopathy
KW - Dilated
KW - Drug therapy
KW - Heart failure
KW - Outcomes assessment
UR - http://www.scopus.com/inward/record.url?scp=84887490363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887490363&partnerID=8YFLogxK
U2 - 10.1161/CIRCHEARTFAILURE.112.000120
DO - 10.1161/CIRCHEARTFAILURE.112.000120
M3 - Article
C2 - 23888044
AN - SCOPUS:84887490363
VL - 6
SP - 913
EP - 921
JO - Circulation: Heart Failure
JF - Circulation: Heart Failure
SN - 1941-3297
IS - 5
ER -